journal
https://read.qxmd.com/read/38181091/evaluation-of-the-prevention-of-mother-to-child-transmission-of-hiv-programs-at-the-second-immunization-visit-in-burkina-faso-and-zambia
#41
JOURNAL ARTICLE
Souleymane Tassembedo, Mwiya Mwiya, Anais Mennecier, Chipepo Kankasa, Paulin Fao, Jean Pierre Molès, Dramane Kania, Catherine Chunda-Liyoka, Leticia Delphine Sakana, Morgana D'Ottavi, Ajani Ousmane Taofiki, David Rutagwera, M M Wilfried-Tonga, Thorkild Tylleskär, Nicolas Nagot, Philippe Van De Perre
OBJECTIVE: Our study aimed to assess the PMTCT indicators in Burkina Faso and Zambia using a patient-orientated innovative strategy based on the second visit in the Expanded Program on Immunization (EPI-2) visit at 6-8 weeks. DESIGN: This was a cross sectional study. METHODS: We assessed women attending EPI-2 at primary healthcare facilities in Burkina Faso and Zambia with their children about their exposure to PMTCT interventions. For women living with HIV (WLHIV), viral load was measured and their children were tested for HIV DNA using point of care devices...
January 4, 2024: AIDS
https://read.qxmd.com/read/38482912/prevalence-and-incidence-of-stroke-among-people-with-hiv-erratum
#42
JOURNAL ARTICLE
(no author information available yet)
No abstract text is available yet for this article.
April 1, 2024: AIDS
https://read.qxmd.com/read/38482911/authors-response-to-comment-on-invisible-but-not-absent
#43
JOURNAL ARTICLE
Kevin M De Cock, Wafaa M El-Sadr
No abstract text is available yet for this article.
April 1, 2024: AIDS
https://read.qxmd.com/read/38482910/to-end-aids-human-rights-must-remain-at-the-center-of-the-hiv-response
#44
JOURNAL ARTICLE
Joseph J Amon
No abstract text is available yet for this article.
April 1, 2024: AIDS
https://read.qxmd.com/read/38482909/adverse-drug-reaction-profile-of-third-generation-smallpox-vaccines-used-in-france-during-the-2022-monkeypox-epidemic
#45
JOURNAL ARTICLE
Audrey Fresse, Nathalie Massy, Dorine Fournier, Sylvine Pinel, Mathilde Beurrier, Marie-Lauren Antoine, Nadine Petitpain, Pierre Gillet
Due to the start of the monkeypox epidemic in 2022, we retrospectively analyzed the adverse drug reactions (ADRs) reported in France after monkeypox vaccinations with the third-generation smallpox vaccine. Ninety-eight cases, representing 172 ADRs, were reported. ADRs were mostly expected reactogenicity reactions occurring within days after the first dose of vaccine and having a quick favorable outcome. Unexpected facial palsy and vaccination failure are discussed.
April 1, 2024: AIDS
https://read.qxmd.com/read/38482908/a-proposal-for-a-simplified-measure-of-hiv-preexposure-prophylaxis-prevention-effective-adherence-in-self-report-questionnaires
#46
JOURNAL ARTICLE
Doug Fraser, Martin Holt, Jason J Ong, Christopher Bourne, Curtis Chan, Andrew E Grulich, Benjamin R Bavinton
Evaluating HIV preexposure prophylaxis (PrEP) use and HIV risk events concurrently remains challenging. We developed a single question method for measuring prevention-effective adherence with PrEP in self-report questionnaires. In a questionnaire completed by 409 gay and bisexual men, 46% reported condomless anal sex that was not covered by their own PrEP use, and this was more common among younger, lower-income participants. Refining this questionnaire item could improve measurement of prevention-effective adherence...
April 1, 2024: AIDS
https://read.qxmd.com/read/38482907/frailty-and-hiv-associated-neurocognitive-disorder-are-only-modestly-associated
#47
JOURNAL ARTICLE
Francisco González-Scarano, Sonia Napravnik, David E Vance
No abstract text is available yet for this article.
April 1, 2024: AIDS
https://read.qxmd.com/read/38416557/authors-response-to-optimizing-behavioral-and-pharmacological-smoking-cessation-interventions-among-people-with-hiv-comment
#48
JOURNAL ARTICLE
Seth S Himelhoch, Jonathan Shuter
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416556/optimizing-behavioral-and-pharmacological-smoking-cessation-interventions-among-people-with-hiv-comment
#49
JOURNAL ARTICLE
Hinpetch Daungsupawong, Viroj Wiwanitkit
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416555/trends-in-hiv-preexposure-prophylaxis-utilization-and-spending-among-individuals-with-commercial-insurance
#50
JOURNAL ARTICLE
Sean Dickson, Katelyn James
In a cross-sectional analysis of HIV preexposure prophylaxis (PrEP) utilization by commercially insured patients from 2019 to 2021, most prescriptions were for branded formulations of PrEP despite the availability of a generic version. Accounting for the modest relative clinical benefit of branded TAF/FTC (tenofovir alafenamide fumarate/emtricitabine) PrEP over generic TDF/FTC (tenofovir disoproxil fumarate/emtricitabine) PrEP, use of generic TDF/FTC PrEP would have reduced commercial insurers' spending by 33%...
March 15, 2024: AIDS
https://read.qxmd.com/read/38416554/hiv-1-envelope-diversity-and-sensitivity-to-broadly-neutralizing-antibodies-across-stages-of-acute-hiv-1-infection
#51
JOURNAL ARTICLE
Laurie A VanderVeen, Lisa Selzer, Brian Moldt, Aiyappa Parvangada, Jiani Li, Jintanat Ananworanich, Trevor A Crowell, Joseph J Eron, Eric S Daar, Richard Haubrich, Romas Geleziunas, Joshua Cyktor, John W Mellors, Christian Callebaut
We studied the relationship between viral diversity and susceptibility to broadly neutralizing antibodies (bNAbs) in longitudinal plasma and peripheral blood mononuclear cells from 89 people with HIV who initiated antiretroviral therapy (ART) during acute and early HIV-1 infection (AEHI). HIV-1 diversity and predicted bNAb susceptibility were comparable across AEHI. Diversity evolution was not observed during ART, suggesting (pro)viruses at initiation or during treatment may identify individuals with susceptible virus for bNAb interventional trials...
March 15, 2024: AIDS
https://read.qxmd.com/read/38416553/is-the-glp-1-receptor-agonist-semaglutide-a-good-option-for-weight-loss-in-persons-with-hiv
#52
JOURNAL ARTICLE
Daniel Lee, Jacqueline Capeau
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416552/reassessing-the-emphasis-on-limited-options-in-antiretroviral-treatment
#53
EDITORIAL
Mauro Zaccarelli
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416551/could-humoral-immune-responses-to-herpesviruses-be-a-pathogenic-driver-of-cognitive-disorders-in-persons-with-hiv
#54
JOURNAL ARTICLE
Alan Winston, Patricia Price
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38416550/a-new-frontier-in-hiv-care-the-predictive-power-of-renal-biomarkers-on-heart-health
#55
EDITORIAL
Silvia Mascolo, Antonio Romanelli
No abstract text is available yet for this article.
March 15, 2024: AIDS
https://read.qxmd.com/read/38061030/bone-turnover-change-after-randomized-switch-from-tenofovir-disoproxil-to-tenofovir-alafenamide-fumarate-in-men-with-hiv
#56
RANDOMIZED CONTROLLED TRIAL
Amelia E B Moore, James E Burns, Deirdre Sally, Ana Milinkovic, Georgios Krokos, Joemon John, Christopher Rookyard, Alessandro Borca, Erica R M Pool, Anna Tostevin, Alyss Harman, Dwight S Dulnoan, Richard Gilson, Alejandro Arenas-Pinto, Gary J R Cook, John Saunders, David Dunn, Glen M Blake, Sarah L Pett
OBJECTIVE: Bone loss in people with HIV (PWH) is poorly understood. Switching tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) has yielded bone mineral density (BMD) increases. PETRAM (NCT#:03405012) investigated whether BMD and bone turnover changes correlate. DESIGN: Open-label, randomized controlled trial. SETTING: Single-site, outpatient, secondary care. PARTICIPANTS: Nonosteoporotic, virologically suppressed, cis-male PWH taking TDF/emtricitabine (FTC)/rilpivirine (RPV) for more than 24 weeks...
March 15, 2024: AIDS
https://read.qxmd.com/read/38300163/lower-aids-related-hospitalizations-in-women-living-with-hiv-multidrug-resistance
#57
JOURNAL ARTICLE
Rebecka Papaioannu Borjesson, Laura Galli, Riccardo Lolatto, Barbara Menzaghi, Marcello Feasi, Roberto Gulminetti, Chiara Fornabaio, Anna Maria Cattelan, Stefano Bonora, Filippo Lagi, Maurizio Zazzi, Antonella Castagna, Vincenzo Spagnuolo
No abstract text is available yet for this article.
March 1, 2024: AIDS
https://read.qxmd.com/read/38300162/people-with-hiv-pioneers-of-injectable-cabotegravir-and-rilpivirine-long-acting-in-italy-who-are-they
#58
MULTICENTER STUDY
Claudia Bartalucci, Federico Baldi, Elena Ricci, Giancarlo Orofino, Barbara Menzaghi, Sergio Ferrara, Giovanni Francesco Pellicano', Nicola Squillace, Eleonora Sarchi, Emanuele Pontali, Giovanni Cenderello, Olivia Bargiacchi, Matteo Piccica, Maria Aurora Carleo, Antonio Cascio, Giuseppe Vittorio De Socio, Paolo Bonfanti, Antonio Di Biagio
Injectable cabotegravir and rilpivirine long-acting therapy is a revolutionary new antiretroviral treatment (ART) option for HIV infection in virologically suppressed adults on a stable ART. The aim of this study from SCOLTA multicenter observational prospective database is to describe the first people living with HIV (PWH) who started this regimen in Italy, assessing adherence to eligibility criteria, describing clinical-epidemiological characteristics compared to registration trials-population and describe early treatment-discontinuations...
March 1, 2024: AIDS
https://read.qxmd.com/read/38300161/criteria-for-classification-nomenclature-and-reference-sequence-selection-for-hiv-sub-subtypes-of-crf01_ae-and-crf07_bc-strains-in-china
#59
JOURNAL ARTICLE
Dong Wang, Yi Feng, Yuhua Ruan, Lingjie Liao, Jingjing Hao, Chang Song, Jing Hu, Yiming Shao, Hui Xing
The available knowledge regarding classification, nomenclature, and reference sequence selection for the various sub-subtypes of circulating recombinant forms (CRFs) is inadequate to fulfill the growing demands of research focused on HIV prevention. We analyzed the spread of CRF01_AE and CRF07_BC strains, mainly in China, to complement and update the existing nomenclature and to propose a reference sequence selection criteria for sub-subtypes of CRFs.
March 1, 2024: AIDS
https://read.qxmd.com/read/38300160/early-adopters-of-long-acting-injectable-cabotegravir-rilpivirine-what-lessons-can-we-learn
#60
JOURNAL ARTICLE
Brian R Wood, Nagalingeswaran Kumarasamy
No abstract text is available yet for this article.
March 1, 2024: AIDS
journal
journal
20006
3
4
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.